Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

[1]  P. Trillenberg,et al.  Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  Keiichi Sakurai,et al.  Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report , 2016, Modern rheumatology.

[3]  Zhengqi Lu,et al.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.

[4]  A. Verkman,et al.  Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. , 2014, Journal of autoimmunity.

[5]  Alex J. Smith,et al.  Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica , 2014, Experimental Neurology.

[6]  J. Palace,et al.  Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab , 2014, Journal of the Neurological Sciences.

[7]  R. Appleton,et al.  A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica , 2014, Autoimmunity.

[8]  R. Appleton,et al.  Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients , 2014, Multiple sclerosis.

[9]  A. Verkman,et al.  Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG , 2014, Acta Neuropathologica.

[10]  M. Papadopoulos,et al.  Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain , 2014, Acta neuropathologica communications.

[11]  Jacqueline A Palace,et al.  Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. , 2014, JAMA neurology.

[12]  Jacqueline A Palace,et al.  Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.

[13]  B. Weinshenker,et al.  The two faces of neuromyelitis optica , 2014, Neurology.

[14]  J. Winters,et al.  The mechanisms of action of plasma exchange , 2014, British journal of haematology.

[15]  M. Papadopoulos,et al.  Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G , 2014, Journal of Neuroinflammation.

[16]  K. Fujihara,et al.  T cell-activation in neuromyelitis optica lesions plays a role in their formation , 2013, Acta neuropathologica communications.

[17]  Y. Kuroiwa,et al.  Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica , 2013, PloS one.

[18]  S. Jarius,et al.  Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link. , 2013, Medical hypotheses.

[19]  F. Paul,et al.  Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) , 2013, Journal of Neurology.

[20]  Jacqueline A Palace,et al.  Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. , 2013, JAMA neurology.

[21]  S. Ram,et al.  Meningococcal disease and the complement system , 2013, Virulence.

[22]  M. Papadopoulos,et al.  Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death , 2013, The Journal of Immunology.

[23]  Su-Hyun Kim,et al.  A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. , 2013, JAMA neurology.

[24]  A. Verkman,et al.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica , 2013, Acta Neuropathologica.

[25]  K. Rostásy,et al.  The spectrum of MOG autoantibody-associated demyelinating diseases , 2013, Nature Reviews Neurology.

[26]  E. Mayatepek,et al.  Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum , 2013, Multiple sclerosis.

[27]  Y. Fragoso,et al.  Neuromyelitis optica and pregnancy , 2013, Journal of Neurology.

[28]  K. Rostásy,et al.  Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica , 2013, Multiple sclerosis.

[29]  F. Nomura,et al.  Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[30]  A. Verkman,et al.  Therapeutic Cleavage of Anti–Aquaporin-4 Autoantibody in Neuromyelitis Optica by an IgG-Selective Proteinase , 2013, Molecular Pharmacology.

[31]  B. Weinshenker,et al.  Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study , 2013, The Lancet Neurology.

[32]  A. Verkman,et al.  C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica , 2013, Acta Neuropathologica.

[33]  A. Verkman,et al.  Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. , 2013, The Journal of clinical investigation.

[34]  F. Nimmerjahn,et al.  The role of Fc receptors and complement in autoimmunity. , 2013, Autoimmunity reviews.

[35]  L. Steinman,et al.  Type I Interferons: Beneficial in Th1 and Detrimental in Th17 Autoimmunity , 2013, Clinical Reviews in Allergy & Immunology.

[36]  T. Kodadek,et al.  Discovery of peptoid ligands for anti-aquaporin 4 antibodies. , 2013, Chemistry & biology.

[37]  J. Palace,et al.  Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies , 2013, Journal of Neurology Neurosurgery & Psychiatry.

[38]  H. Hartung,et al.  Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. , 2013, JAMA neurology.

[39]  R. Gold,et al.  Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. , 2013, JAMA neurology.

[40]  B. Casanova,et al.  The effect of intravenous immunoglobulin on neuromyelitis optica , 2013 .

[41]  F. Coret,et al.  The effect of intravenous immunoglobulin on neuromyelitis optica. , 2013, Neurologia.

[42]  R. Takahashi,et al.  Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica , 2013, Journal of Neurology.

[43]  A. Verkman,et al.  Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti–aquaporin‐4 immunoglobulin G into therapeutic antibody , 2013, Annals of neurology.

[44]  M. Papadopoulos,et al.  Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions , 2012, Neuroreport.

[45]  M. Papadopoulos,et al.  Neuromyelitis optica IgG does not alter aquaporin‐4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly , 2012, Glia.

[46]  E. Gelfand.  Intravenous immune globulin in autoimmune and inflammatory diseases. , 2012, The New England journal of medicine.

[47]  K. Fujihara,et al.  Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[48]  J. Bluestone,et al.  Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. , 2012, Cold Spring Harbor perspectives in biology.

[49]  A. Traboulsee,et al.  Treatment of Neuromyelitis Optica: Review and Recommendations. , 2012, Multiple sclerosis and related disorders.

[50]  Jacqueline A Palace,et al.  Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype , 2012, Neurology.

[51]  A. Verkman,et al.  A Small-molecule Screen Yields Idiotype-specific Blockers of Neuromyelitis Optica Immunoglobulin G Binding to Aquaporin-4* , 2012, The Journal of Biological Chemistry.

[52]  J. Tillema,et al.  The Spectrum of Neuromyelitis Optica (NMO) in Childhood , 2012, Journal of child neurology.

[53]  O. Hammer.  CD19 as an attractive target for antibody-based therapy , 2012, mAbs.

[54]  T. Yamamura,et al.  Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab , 2012, Modern rheumatology.

[55]  E. M. Oliveira,et al.  Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. , 2012, Archives of neurology.

[56]  S. Olindo,et al.  Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. , 2012, Archives of ophthalmology.

[57]  R. Stroud,et al.  Aquaporin 4-Specific T Cells in Neuromyelitis Optica Exhibit a Th17 Bias and Recognize Clostridium ABC Transporter , 2012, Annals of neurology.

[58]  A. Wu,et al.  Notable Increased Cerebrospinal Fluid Levels of Soluble Interleukin-6 Receptors in Neuromyelitis Optica , 2012, Neuroimmunomodulation.

[59]  M. Papadopoulos,et al.  Aquaporin 4 and neuromyelitis optica , 2012, The Lancet Neurology.

[60]  K. Fujihara,et al.  Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. , 2012, Brain : a journal of neurology.

[61]  M. Papadopoulos,et al.  Small‐molecule inhibitors of NMO‐IgG binding to aquaporin‐4 reduce astrocyte cytotoxicity in neuromyelitis optica , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  M. Papadopoulos,et al.  Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss , 2012, Acta Neuropathologica.

[63]  H. Kim,et al.  Influence of pregnancy on neuromyelitis optica spectrum disorder , 2012, Neurology.

[64]  M. Papadopoulos,et al.  Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence , 2012, Multiple sclerosis.

[65]  A. Verkman,et al.  Complement-dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal Arrays* , 2012, The Journal of Biological Chemistry.

[66]  M. Papadopoulos,et al.  Anti–Aquaporin‐4 monoclonal antibody blocker therapy for neuromyelitis optica , 2012, Annals of neurology.

[67]  M. Papadopoulos,et al.  Neutrophil protease inhibition reduces neuromyelitis optica–immunoglobulin G–induced damage in mouse brain , 2012, Annals of neurology.

[68]  C. Sindic,et al.  Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network , 2012, Journal of Neuroimmunology.

[69]  Su-Hyun Kim,et al.  Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? , 2012, Multiple sclerosis.

[70]  F. Paul,et al.  Failure of natalizumab to prevent relapses in neuromyelitis optica. , 2012, Archives of neurology.

[71]  P. Cabre,et al.  Plasma Exchange in Severe Attacks of Neuromyelitis Optica , 2012, Multiple sclerosis international.

[72]  E. Frohman,et al.  Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success , 2012, Multiple sclerosis.

[73]  F. Paul,et al.  Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients , 2012, Journal of Neuroinflammation.

[74]  B. Kim,et al.  Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder , 2012, Multiple sclerosis.

[75]  M. Barnett,et al.  Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy , 2012, Multiple sclerosis.

[76]  A. Lutterotti,et al.  Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders , 2011, Journal of Neuroinflammation.

[77]  A. Verkman,et al.  Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms , 2011, Annals of neurology.

[78]  M. Romero,et al.  Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes , 2011, Proceedings of the National Academy of Sciences.

[79]  T. Kanda,et al.  Sera from neuromyelitis optica patients disrupt the blood–brain barrier , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[80]  Su-Hyun Kim,et al.  Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. , 2011, Archives of neurology.

[81]  A. Verkman,et al.  Evidence against Cellular Internalization in Vivo of NMO-IgG, Aquaporin-4, and Excitatory Amino Acid Transporter 2 in Neuromyelitis Optica* , 2011, The Journal of Biological Chemistry.

[82]  Y. Li,et al.  Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse , 2011, Journal of Clinical Neuroscience.

[83]  B. Lam,et al.  Impact of rituximab on relapse rate and disability in neuromyelitis optica , 2011, Multiple sclerosis.

[84]  B. Weinshenker,et al.  Genetic analysis of aquaporin-4 in neuromyelitis optica , 2011, Neurology.

[85]  G. Illei,et al.  Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus , 2011, Annals of the rheumatic diseases.

[86]  B. Weinshenker,et al.  Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica , 2011, Neurology.

[87]  R. Bergamaschi,et al.  Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures , 2011, Journal of the Neurological Sciences.

[88]  H. Kita.  Eosinophils: multifaceted biological properties and roles in health and disease , 2011, Immunological reviews.

[89]  T. Hanafusa,et al.  Increased serum matrix metalloproteinase-9 in neuromyelitis optica: Implication of disruption of blood–brain barrier , 2011, Journal of Neuroimmunology.

[90]  Masatoyo Nishizawa,et al.  Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[91]  M. Papadopoulos,et al.  T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement , 2011, Journal of Neuroimmunology.

[92]  K. Kyvik,et al.  A population-based study of neuromyelitis optica in Caucasians , 2011, Neurology.

[93]  Y. Li,et al.  Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis , 2011, Journal of Neuroimmunology.

[94]  M. Krumbholz,et al.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab , 2011, Neurology.

[95]  Su-Hyun Kim,et al.  Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. , 2011, Archives of neurology.

[96]  A. Verkman,et al.  Binding Affinity and Specificity of Neuromyelitis Optica Autoantibodies to Aquaporin-4 M1/M23 Isoforms and Orthogonal Arrays* , 2011, The Journal of Biological Chemistry.

[97]  A. Damiano.  Review: Water channel proteins in the human placenta and fetal membranes. , 2011, Placenta.

[98]  T. Yamamura,et al.  Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica , 2011, Proceedings of the National Academy of Sciences.

[99]  C. Berek,et al.  Eosinophils are required for the maintenance of plasma cells in the bone marrow , 2011, Nature Immunology.

[100]  T. Kanda,et al.  A serological analysis of viral and bacterial infections associated with neuromyelitis optica , 2011, Journal of the Neurological Sciences.

[101]  S. Olindo,et al.  Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population , 2011, Multiple sclerosis.

[102]  Jianrong Li,et al.  Astrocytes promote TNF‐mediated toxicity to oligodendrocyte precursors , 2011, Journal of neurochemistry.

[103]  P. Huppke,et al.  Neuromyelitis optica and NMO-IgG in European pediatric patients , 2010, Neurology.

[104]  Abdul Hakkim,et al.  Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps , 2010, The Journal of cell biology.

[105]  B. Hemmer,et al.  Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. , 2010, Archives of neurology.

[106]  D. Bichuetti,et al.  Neuromyelitis optica treatment: analysis of 36 patients. , 2010, Archives of neurology.

[107]  F. Paul,et al.  Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance , 2010, Journal of Neuroinflammation.

[108]  S. Tsuji,et al.  IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum , 2010, Neurology.

[109]  Jacqueline A Palace,et al.  Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. , 2010, Archives of neurology.

[110]  B. Weinshenker,et al.  Familial neuromyelitis optica , 2010, Neurology.

[111]  Brigitte Wildemann,et al.  AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance , 2010, Nature Reviews Neurology.

[112]  M. Sahraian,et al.  Relapsing Neuromyelitis Optica: demographic and clinical features in Iranian patients , 2010, European journal of neurology.

[113]  M. Papadopoulos,et al.  Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. , 2010, Brain : a journal of neurology.

[114]  E. Donadi,et al.  HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis , 2010, Multiple sclerosis.

[115]  F. Paul,et al.  A woman with acute myelopathy in pregnancy: case outcome , 2009, BMJ : British Medical Journal.

[116]  S. Kusunoki,et al.  Intermittent Plasmapheresis Prevents Recurrence in Neuromyelitis Optica , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[117]  S. Jacob,et al.  Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies , 2009, Current neuropharmacology.

[118]  B. Hemmer,et al.  Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica , 2009, Annals of neurology.

[119]  T. Tedder.  CD19: a promising B cell target for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[120]  B. Song,et al.  Reactive Astrocytes Form Scar-Like Perivascular Barriers to Leukocytes during Adaptive Immune Inflammation of the CNS , 2009, The Journal of Neuroscience.

[121]  P. Zipfel,et al.  Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.

[122]  A. Warth.  Prevention of orthogonal array of particles formation as a treatment approach for neuromyelitis optica. , 2009, Medical hypotheses.

[123]  Francesco Saverio Tedesco,et al.  Complement in human diseases: Lessons from complement deficiencies. , 2009, Molecular immunology.

[124]  B. Weinshenker,et al.  Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. , 2009, Archives of neurology.

[125]  D. West,et al.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2009, The Lancet. Oncology.

[126]  R. Hohlfeld,et al.  Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab , 2009, Multiple sclerosis.

[127]  P. López-Saura,et al.  TNF-α and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica , 2009, Journal of Inflammation.

[128]  S. Olindo,et al.  Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder , 2009, Multiple sclerosis.

[129]  P. Vermersch,et al.  Is neuromyelitis optica associated with human leukocyte antigen? , 2009, Multiple sclerosis.

[130]  J. Kurtzke,et al.  An epidemiological study of neuromyelitis optica in Cuba , 2009, Journal of Neurology.

[131]  J. Lundgren,et al.  Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation , 2009, Multiple sclerosis.

[132]  J. Kira,et al.  Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. , 2009, Tissue antigens.

[133]  J. Hunter,et al.  Spectrum of Pediatric Neuromyelitis Optica , 2008, Pediatrics.

[134]  C. Lucchinetti,et al.  Aquaporin-4–binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2 , 2008, The Journal of experimental medicine.

[135]  A. Vincent,et al.  Antibody to aquaporin-4 in the long-term course of neuromyelitis optica , 2008, Brain : a journal of neurology.

[136]  A. Bar-Or,et al.  Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment1 , 2008, The Journal of Immunology.

[137]  Aaron E Miller,et al.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. , 2008, Archives of neurology.

[138]  M. Bradl,et al.  Anti-aquaporin-4 antibodies in neuromyelitis optica: how to prove their pathogenetic relevance? , 2008, International MS journal.

[139]  B. Weinshenker,et al.  CNS aquaporin-4 autoimmunity in children , 2008, Neurology.

[140]  F. Paul,et al.  Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica , 2008, Nature Clinical Practice Neurology.

[141]  A. Kermode,et al.  Characterisation of the spectrum of demyelinating disease in Western Australia , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[142]  A. Bar-Or,et al.  Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders , 2008, Neurology.

[143]  G. Rajshekher,et al.  IDIOPATHIC TRANSVERSE MYELITIS: CORTICOSTEROIDS, PLASMA EXCHANGE, OR CYCLOPHOSPHAMIDE , 2008, Neurology.

[144]  C. Lucchinetti,et al.  Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica , 2007, Neurology.

[145]  John D Lambris,et al.  Complement-targeted therapeutics , 2007, Nature Biotechnology.

[146]  D. Arnold,et al.  Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial , 2007 .

[147]  D. Yuksel,et al.  Devic's Neuromyelitis Optica in an Infant Case , 2007, Journal of child neurology.

[148]  A. De Luca,et al.  Down-regulation of aquaporin 4 in human placenta throughout pregnancy. , 2007, In vivo.

[149]  Y. Itoyama,et al.  Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis , 2007, Multiple sclerosis.

[150]  F. Mihara,et al.  Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. , 2007, Brain : a journal of neurology.

[151]  B. Weinshenker,et al.  A secondary progressive clinical course is uncommon in neuromyelitis optica , 2007, Neurology.

[152]  Y. Matsumoto,et al.  Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination , 2007, Journal of the Neurological Sciences.

[153]  T. Dóczi,et al.  Fetal development of membrane water channel proteins aquaporin-1 and aquaporin-4 in the human brain , 2006, International Journal of Developmental Neuroscience.

[154]  M. Ramanathan,et al.  Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). , 2006, Archives of neurology.

[155]  H. Weiner,et al.  Oral Tolerance: Therapeutic Implications for Autoimmune Diseases , 2006, Clinical & developmental immunology.

[156]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.

[157]  P. Barnes.  Corticosteroids: the drugs to beat. , 2006, European journal of pharmacology.

[158]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[159]  Y. Itoyama,et al.  Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[160]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[161]  E. Waubant,et al.  An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.

[162]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[163]  L. Metz,et al.  Devic's Neuromyelitis Optica Treated with Intravenous Gamma Globulin (IVIG) , 2004, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[164]  S. Shapiro,et al.  Neutrophil Elastase (NE)-Deficient Mice Demonstrate a Nonredundant Role for NE in Neutrophil Migration, Generation of Proinflammatory Mediators, and Phagocytosis in Response to Zymosan Particles In Vivo1 , 2004, The Journal of Immunology.

[165]  Ngan B. Doan,et al.  Reactive Astrocytes Protect Tissue and Preserve Function after Spinal Cord Injury , 2004, The Journal of Neuroscience.

[166]  Hans Lassmann,et al.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. , 2002, Brain : a journal of neurology.

[167]  B. Weinshenker,et al.  Plasma exchange for severe attacks of CNS demyelination: Predictors of response , 2002, Neurology.

[168]  A. Olsén,et al.  EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG , 2001, The EMBO journal.

[169]  P. Cabre,et al.  MS and neuromyelitis optica in Martinique (French West Indies) , 2001, Neurology.

[170]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[171]  E. Nagelhus,et al.  Ontogeny of water transport in rat brain: postnatal expression of the aquaporin‐4 water channel , 1999, The European journal of neuroscience.

[172]  Acknowledgements , 1992, Experimental Gerontology.

[173]  M. Suzuki,et al.  ONO-5046, a novel inhibitor of human neutrophil elastase. , 1991, Biochemical and biophysical research communications.

[174]  Victor C. Strasburger,et al.  Review and Recommendations , 1983 .

[175]  A. Hirt,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.

[176]  Benchara Branford,et al.  Reviews , 1920 .

[177]  Manjit,et al.  Neurology , 1912, NeuroImage.

[178]  C. Wegner,et al.  Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions , 2013, Acta Neuropathologica.

[179]  H. Sasaki,et al.  Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. , 2013, Internal medicine.

[180]  Daniel Ricklin,et al.  Progress and Trends in Complement Therapeutics. , 2013, Advances in experimental medicine and biology.

[181]  恭一 野村,et al.  フィンゴリモド投与10日後に多巣性白質病変を呈し急性増悪を示した視神経脊髄炎関連疾患（NMOSD）の1例 , 2013 .

[182]  V. Bittencourt,et al.  The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients , 2012, Journal of Clinical Immunology.

[183]  K. Iwata,et al.  Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. , 2010, Internal medicine.

[184]  K. Kabashima,et al.  Immunopathology and Infectious Diseases FTY 720 Regulates Bone Marrow Egress of Eosinophils and Modulates Late-Phase Skin Reaction in Mice , 2010 .

[185]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[186]  松岡 健.  Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese , 2009 .

[187]  S. Tsuji,et al.  Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. , 2007, Internal medicine.

[188]  P. Lachmann,et al.  Membrane defence against complement lysis: The structure and biological properties of CD59 , 1993, Immunologic research.

[189]  Evon M. O. Abu-Taieh,et al.  Comparative Study , 2020, Definitions.

[190]  M. F. Parry,et al.  A Retrospective Analysis , 1990 .